Skip to main content

Advertisement

Table 2 Treatment characteristics between SBRT and CF-EBRT

From: Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT)

Variable SBRT (n = 36) CF-EBRT (n = 17)
Location, n (%)   
 Thorax 27 (75 %) 9 (53 %)
 Skin & Soft Tissue 3 (8.3 %) 5 (29 %)
 Abdomen 6 (16.7 %) 3 (18 %)
Median Dose Per Fraction (range, Gy) 10 (5–25) 4 (2.5–4)
Median Tumor Size (range, mm)* 21 (4–87) 23 (15–57)
Gross Tumor Volume (GTV) (range, cm3) 5.14 (0.93–184.07) -
Planned Tumor Volume (PTV) (range, cm3) 20.01 (6.00–295.51) -
Biological Effective Dose (BED) (range) 216.67 (66.67–460) 60.00 (46.67–100.83)
Systemic Therapy Prior to Radiation, n (%)   
 Yes 26 (72 %) 12 (71 %)
 No 10 (28 %) 5 (29 %)
Systemic Therapy After Radiation, n (%)   
 Yes 20 (55 %) 10 (59 %)
 No 16 (45 %) 7 (41 %)
  1. GTV gross tumor volume, PTV planned tumor volume, BED biologic effective dose
  2. *As determined from the greatest tumor dimension by pre-treatment radiographic imaging. No difference was found between the two groups via t-test comparison (p = 0.357)